Midamor

Quick links to important sections

Midamor

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Midamor

Quick Facts

Property Description
Active ingredient Amiloride hydrochloride
Form Tablet (Oral solid dosage form)
Pharmacological class Potassium-sparing diuretic
General action Fluid and salt excretion, potassium conservation
Origin Synthetic compound (Pyrazine derivative)

What is Midamor? Drug Type and Core Classification

Midamor is the trade name for a prescription medicine defined by its active component, Amiloride hydrochloride. It is consistently formulated as an oral tablet containing this single active ingredient. The medicine is categorized as a diuretic, specifically belonging to the group known as potassium-sparing diuretics, a classification used for its utility in managing fluid balance.

Composition, Form, and Origin of Amiloride

The substance, Amiloride, is a synthetic compound manufactured through chemical synthesis, confirming it is not naturally derived. The final preparation is an oral solid dosage form (tablet) containing the active salt along with essential inactive solid excipients. This single-ingredient composition ensures that its action is focused on its primary mechanism of regulating electrolyte balance.

What is the General Purpose of a Potassium-Sparing Diuretic?

The primary general purpose of Amiloride is to enhance the excretion of excess salt and water through the kidneys while uniquely preventing the loss of potassium, an action often described as being antikaliuretic. This class of medicine functions by blocking the reabsorption of sodium, which leads to increased water and salt excretion. This specialized feature is integral to the drug's utility, serving to manage fluid-related issues while protecting against electrolyte imbalance.

What side effects are possible with Midamor?

Possible Side Effects and Safety Information

The safety profile of Midamor (Amiloride hydrochloride) is primarily defined by its core pharmacological action as a potassium-sparing diuretic, with the most significant safety concern being the potential for hyperkalemia (elevated serum potassium levels). Uncorrected hyperkalemia is documented in official labeling as a potentially fatal adverse effect which can lead to life-threatening cardiac arrhythmias.

Adverse reactions are classified into various System-Organ Classes as documented in regulatory sources:

  • Metabolism and Nutrition Disorders: The most common concern is the rise in serum potassium levels (hyperkalemia). Other reported imbalances include hyponatremia and hyperuricemia.
  • Gastrointestinal Disorders: Commonly reported effects include nausea, anorexia, vomiting, diarrhea, abdominal pain, and gas pain. Less common reports include constipation, jaundice, and gastrointestinal bleeding.
  • Nervous System and Psychiatric Disorders: Reported effects include headache, weakness, fatigue, dizziness, and tremors.

Frequency Classification: Common adverse effects include headache, weakness, fatigue, and hyperkalemia. Less common effects (Incidence le 1%) include orthostatic hypotension, arrhythmias, and skin rash. Rare post-marketing reports include aplastic anaemia and neutropenia.

Serious Safety Considerations and Restrictions: The risk of hyperkalemia is accentuated in patients with renal impairment, diabetes mellitus, and in older adults. Midamor is explicitly restricted (contraindicated) in individuals with severe renal impairment (including anuria), pre-existing hyperkalemia, or when used concomitantly with other potassium-sparing agents or potassium supplements.

Overdose and Emergency Response

Midamor Overdose and When to Seek Help

Overdose with Midamor (amiloride hydrochloride) is primarily characterized by the officially documented physiological consequences of exaggerated fluid and electrolyte disturbances. Due to the drug's potassium-sparing action, a central feature of overdose is the potential for severe hyperkalemia (elevated serum potassium), which is formally described as a potentially life-threatening complication.

Attribute Official Regulatory Documentation
Documented Overdose Presentations Profound Diuresis leading to Dehydration; Electrolyte imbalances, including Hyponatremia and Hyperkalemia; Hypotension (low blood pressure).
Physiological Systems Affected Fluid and Electrolyte Balance, Cardiovascular System, Renal System.
Population-specific Overdose Notes Risk of severe hyperkalemia is specifically increased in patients with Impaired Renal Function.

The most severe, officially documented outcomes include circulatory collapse and cardiac arrhythmias which can rapidly progress to cardiac arrest due to the hyperkalemia. Immediate medical intervention is required for any suspected overdose.

Regulatory documents mandate that individuals seek immediate medical attention or contact emergency services if overdose is suspected. The official labeling states that no specific antidote is known for amiloride overdose. Consequently, treatment is strictly defined as symptomatic and supportive treatment, requiring hospital monitoring of serum electrolytes and fluid status. Hemodialysis is officially stated as not being an effective removal method.

Therapeutic Uses of Midamor

Midamor (amiloride) is a prescription medicine primarily used as an adjunct therapy alongside other diuretics to manage various conditions involving fluid retention and mineral imbalance. It is often prescribed to support treatment for fluid accumulation, known as edema, associated with conditions such as congestive heart failure and cirrhosis of the liver. Midamor may be used to help increase the removal of excess water and salt through the kidneys, which contributes to easing the physical burden of fluid buildup.

The medicine's key clinical benefit is its specific action in potassium conservation. Many common diuretics can lead to hypokalemia (low potassium levels), which can negatively impact heart function. Midamor assists in the management of this potential mineral imbalance, helping to support overall electrolyte stability. This makes it valuable in clinical scenarios involving hypertension (high blood pressure) and heart failure, where it is typically combined with other medications.


Quick Fact: Relief for Fluid Retention (Edema)


Eligibility and Restrictions for Use

Midamor (Amiloride) eligibility is strictly defined by government regulatory documents, focusing on potassium balance and renal function.

Absolute Contraindications

The medicine is formally contraindicated and must not be used by patients with:

  • Hyperkalemia (elevated serum potassium).
  • Severe Renal Impairment, including anuria, acute/chronic renal failure, or diabetic nephropathy.
  • Concomitant use of other potassium-sparing diuretics or routine potassium supplements.
  • Known hypersensitivity to Amiloride.

Restricted and Conditional Use

Use is restricted, requires special caution, and necessitates frequent monitoring in specific populations:

  • Impaired Renal Function: Patients with evidence of moderate renal impairment (elevated BUN or creatinine) may use the drug only with rigorous oversight of electrolytes and kidney function.
  • Comorbidities: Use should generally be avoided in patients with Diabetes Mellitus. It also requires caution in patients with Hepatic Cirrhosis and those at risk for Metabolic Acidosis.
  • Age and Status: Safety and efficacy have not been established in pediatric patients (under 18 years), and use in older adults requires specific caution. Use during pregnancy is not recommended due to limited clinical data.

What should I know about interactions with other medicines?

Midamor (amiloride) interaction profile is defined primarily by pharmacodynamic synergism that increases potassium levels and by effects on the clearance of other medicines, as documented in official regulatory labeling.

Interaction Classifications (High-Level)

Classification Interacting Medicines/Categories
Contraindicated Combinations Potassium-conserving agents (e.g., Spironolactone, Triamterene); Potassium supplementation (medication, salt substitutes, potassium-rich diet); Elevated serum potassium (levels >5.5 mEq/L).
Clinically Significant Interactions Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Antagonists (ARBs); Lithium; Immunosuppressants (Ciclosporin, Tacrolimus); Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Official Interaction Statements

  • Co-administration with other potassium-conserving agents is formally contraindicated due to the high risk of severe hyperkalemia.
  • Amiloride reduces the renal clearance of Lithium, which can lead to increased plasma concentrations and a high risk of toxicity. Co-administration is generally restricted.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can reduce the diuretic and blood pressure-lowering effects of amiloride, and increase the risk of hyperkalemia, particularly with Indomethacin.
  • Enhanced hypotensive effects may occur when amiloride is co-administered with other antihypertensive agents.
  • Population-specific interaction constraints exist: The hyperkalemic risk associated with interactions is accentuated in patients with renal impairment and in those with diabetes mellitus.
  • A mandatory timing-based rule requires amiloride to be discontinued for at least three days before glucose-tolerance testing in diabetic patients.

The regulatory documents define the product's interaction structure primarily through its potassium-sparing property, which dictates all major co-administration restrictions based on the resulting increased risk of hyperkalemia.

Mechanism of Action

How Midamor Works

Midamor (Amiloride) acts through two primary, interconnected mechanistic domains that mediate its physiological effects: targeted sodium blockade and potassium secretion modulation. The mechanism is localized to the kidney and affects the regulation of electrolytes and water.

Targeted Blockade of Sodium Reabsorption ( ENaC)

Amiloride directly blocks the Epithelial Sodium Channel ( ENaC) located on the apical membrane of principal cells in the distal segments of the kidney tubules. By inhibiting the reabsorption of sodium ions ( Na^+), the drug ensures that more Na^+ remains in the tubular fluid. The presence of excess Na^+ compels water to be excreted with the salt via osmotic force. This process directly initiates natriuresis (salt excretion) and diuresis (water excretion), leading to a reduction in total body fluid volume.

️ Antikaliuretic Action and Electrical Gradient Modulation

Blocking ENaC eliminates the lumen-negative electrical potential normally generated by sodium reabsorption. Since this potential is the essential driving force for the secretion of potassium ions ( K^+) and hydrogen ions ( H^+) into the urine, its loss results in the suppression of K^+ and H^+ secretion. This mechanism-driven effect results in the reduction of potassium secretion, characterizing the drug's action as antikaliuretic.

Dosage and Administration Information

Midamor, an oral solid dosage form containing Amiloride hydrochloride, is administered exclusively by the oral route. The medication is generally intended for use as adjunctive treatment with other diuretic agents; it is generally recognized that the medicine should rarely be used alone.

The standard dosing schedule for adults begins with an initial dose of 5 mg taken once daily. Maintenance dosing typically ranges from 5 mg to 10 mg daily, which may be administered once a day or in divided doses. The maximum dose for daily administration is 20 mg. The final dose is adjusted based on the patient's individual response to the medication.

For proper administration, the tablet should be taken with food, and if used concurrently with an intermittent diuretic, both agents should be taken at the same time. The medicine is not recommended for use in pediatric patients. Specific dose adjustments are required for older adults, often based on renal function, and use is generally avoided in patients with significant kidney impairment. If a dose is missed, the missed amount is skipped if it is close to the time of the next scheduled dose, and the user should never double the dose to compensate.

Recent Clinical Evidence

Midamor: Recent Clinical Evidence

Midamor (amiloride) is a potassium-sparing diuretic that has been widely studied, primarily in combination with other diuretics, for its effects on blood pressure and fluid balance. Recent clinical research has focused on its use in specific patient populations, particularly those with resistant hypertension and certain cardiovascular markers.


Resistant Hypertension

A key area of recent research has compared amiloride with spironolactone as an add-on treatment for resistant hypertension (high blood pressure not controlled by a standard three-drug regimen).

  • Study Findings: A randomized clinical trial involving patients with resistant hypertension found that amiloride was noninferior to spironolactone in lowering home-measured systolic blood pressure (SBP) after 12 weeks. The reduction in SBP was comparable between the amiloride group and the spironolactone group.
  • Implication: This evidence supports the consideration of amiloride as an alternative fourth-line agent for patients with resistant hypertension, particularly in situations where spironolactone may not be tolerated.

Cardiovascular and Organ Effects

Research has also explored the potential effects of amiloride beyond blood pressure and fluid removal, focusing on specific cardiovascular markers:

  • Neuroprotection: Early research has investigated amiloride's potential neuroprotective properties in conditions like optic neuritis (inflammation of the optic nerve), focusing on its mechanism as an epithelial sodium channel (ENaC) blocker. These studies assess outcomes such as visual function and the preservation of retinal nerve fiber thickness.
  • Arrhythmia Markers: In a small-scale study of patients with chronic heart failure, amiloride was observed to shorten QT interval indices and reduce ventricular extrasystoles, suggesting an effect on electrical stability that may be related to its potassium-retaining mechanism.

Frequently Asked Questions (FAQ)

Common questions about Midamor (FAQ)


Q: Do I need to change my diet when taking Midamor?

Official prescribing information indicates that treatment for high blood pressure may involve managing weight and adjusting the intake of sodium. Since Midamor is a potassium-sparing medicine, it is particularly important to avoid consuming potassium-rich foods or using salt substitutes that contain potassium, as this can lead to elevated potassium levels. Dietary adjustments should be discussed with a healthcare provider.


Q: Can Midamor affect my blood sugar levels?

Regulatory documents caution that Midamor should be used with extra care, or possibly avoided, in patients with Diabetes Mellitus. This is primarily because people with diabetes are at a greater risk of developing high potassium levels (hyperkalemia) when using this medication. Official guidelines require the drug to be discontinued for a period before glucose-tolerance testing is administered.


Q: Is Midamor a commonly prescribed drug in people with liver disease?

Official product information states that Midamor must be used with caution in patients who have severe liver disease, such as hepatic cirrhosis. This medicine may increase the chance of certain side effects, including a condition called encephalopathy (brain function issues) induced by metabolic changes. Official guidance indicates that its use in this patient group requires careful oversight.


Q: Is there research evidence showing how effective Midamor is for heart failure?

According to official labeling, Midamor is indicated as an add-on treatment alongside other diuretics for managing congestive heart failure. Its primary recognized role in this context is for potassium conservation, often described as adjunctive treatment.


Q: Does Midamor cause or worsen gout?

The medicine may cause an increase in the amount of uric acid in the blood, a condition known as hyperuricemia, which is the underlying cause of gout. Some regulatory documents list gout as a reported adverse effect or a condition that requires caution. Patients with a history of gout or hyperuricemia should discuss this with their healthcare provider.


Q: Do the side effects of Midamor usually go away over time?

Official patient guidance states that you should inform your health professional if side effects are severe or do not go away over time. This implies that some adverse effects may lessen or be temporary, but regulatory labels do not specify a fixed duration for when side effects should resolve. Official guidance advises contacting a health professional if side effects are severe or do not resolve.


Q: Does Midamor cause weight gain or weight loss?

Official safety information reports that weight loss has been observed as a less common side effect of Midamor. This effect is thought to be linked to other common adverse effects like a loss of appetite and nausea. Weight gain is not listed as a direct side effect.


Q: How long does it usually take for Midamor to start lowering blood pressure?

The diuretic (water-excreting) effect of the active ingredient, amiloride, typically begins quickly, often within two hours after taking an oral dose. The peak effect on salt and water excretion is usually reached between six to ten hours, with the full effect lasting about 24 hours.


Q: Is Midamor safe to take long-term for high blood pressure?

Official guidance confirms that Midamor is a medicine used to control high blood pressure, which is a chronic condition and is not curable by the medication. For this reason, official patient information indicates that, for chronic conditions like high blood pressure, taking the medicine long-term may be necessary to maintain control.


Q: Is there a maximum time someone can be on Midamor?

According to official patient guidance for high blood pressure management, the treatment often continues long-term. Because the medicine is intended to help control a chronic condition, regulatory guidance implies no specified maximum duration, indicating that, for chronic conditions, it may be required long-term.


Q: What happens if Midamor is stopped suddenly?

Official patient instructions advise against stopping the medication suddenly without consulting your healthcare provider, even if you feel well. Abrupt discontinuation may be associated with the loss of blood pressure control or a return of fluid balance issues.


Q: Can Midamor affect sleep patterns?

Official safety documentation reports that adverse effects on sleep have been noted in some patients. These reported effects include difficulty sleeping, known as sleeplessness (insomnia), and, less commonly, feeling unusually drowsy (sleepiness).


Q: Is it safe to drink alcohol in moderation while taking Midamor?

Official drug interaction databases indicate that combining Midamor with alcohol may have additive effects in lowering blood pressure. This additive effect may be associated with symptoms such as dizziness, lightheadedness, or fainting.

How should Midamor be stored and disposed of?

Storage and Disposal Requirements for Midamor

Midamor (amiloride hydrochloride) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Storage conditions require protection from excess heat, moisture, and direct light. It is explicitly mandated that the medicine must not be frozen.

Container and Child Safety

The tablets must be kept in their original container, and the container should be tightly closed to maintain product integrity. The medicine must be stored out of the reach and sight of children.

Disposal of Unused Medicine

The officially recommended method for disposing of unused or expired Midamor is through a community drug take-back program. If a take-back program is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash, following regulatory guidelines. Personal information on the prescription label must be removed prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Midamor found in:

A-Z Index: